Mojia Bioscience
A biotech company that provides solutions to human and nature's needs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $80.0m | Series B | |
| Total Funding | 000k | ||
Related Content
Mojia Bioscience is a biomanufacturing firm focused on displacing conventional, petroleum-based chemical production with more sustainable, bio-based alternatives. Founded in 2018 and headquartered in Shanghai, the company operates at the intersection of biology and chemistry, utilizing a comprehensive R&D platform that integrates biology, chemistry, engineering, and polymer sciences. This platform leverages proprietary technologies like enzyme engineering, metabolic pathway engineering, and AI-assisted tools to develop green manufacturing processes.
The company was co-founded by Ansen Chiew, with Dr. Kevin Li serving as Chairman. Mojia Bioscience has established a global presence with R&D activities and partnerships in the U.S., Singapore, and China, along with manufacturing facilities in China. The firm's business model is centered on the large-scale production and commercialization of bio-based products that offer both cost advantages and superior performance compared to traditional chemical industry outputs. This strategy aims to mitigate environmental issues like high energy consumption, pollution, and greenhouse gas emissions associated with petrochemical manufacturing.
Mojia Bioscience has two flagship product lines. The first is Viridimin®, a brand of Vitamin B5 produced via a patented bio-process. This product serves as an essential nutrient and is used as an additive in animal feed and for fortifying human foods such as cereals and dairy products. The bio-process for Viridimin® is designed to consume less energy and produce less waste than conventional methods. The second major product line is Aliphane®, a series of bio-based polymer products. Aliphane® materials are versatile and used in high-performance coatings, adhesives, sealants, and elastomers across various industries, including automotive, construction, footwear, and renewable energy.
The company has successfully secured significant funding to scale its operations. In August 2020, it raised over 100 million RMB in a Series A round. This was followed by a substantial $80 million Series B financing round in June 2022, led by Temasek, with participation from investors like Asia Green Fund, LYZZ Capital, and Bits x Bites. This capital is being used to commercialize its product portfolio, scale up manufacturing capacity, and expand its global R&D capabilities.
Keywords: biomanufacturing, synthetic biology, sustainable chemicals, enzyme engineering, metabolic engineering, green chemistry, bio-based polymers, animal feed additives, Vitamin B5, Aliphane, Viridimin, industrial biotechnology, renewable carbon sources, circular bioeconomy, sustainable manufacturing, specialty chemicals, bio-based materials, decarbonization, polyurethane systems, food ingredients